Subscribe

Lifeist Wellness Inc. (LFST.V)

CAD0.04 +0.00 (+0.00%)
CA TSXV Healthcare Drug Manufacturers - Specialty & Generic
Address 666 Burrard Street V6C 2X8
Vancouver, BC, CA
CEO David Hughes
Website lifeist.com
IPO 2018-05-03
ISIN CA53228D2059

Explore sections of this company profile

Also trades on Other OTC · NXTTF (USD) Toronto Stock Exchange Ventures · LFST.V (CAD)
Description

Headquartered in Vancouver, Canada, and established in 2005, Lifeist Wellness Inc. (formerly Namaste Technologies Inc. until September 2021) operates as a multifaceted wellness enterprise across the United States and Canada. Its diverse portfolio includes CannMart.com, an online retail destination for hemp-derived CBD and accessories. The company also owns Findify, an artificial intelligence-powered platform that delivers personalized search, recommendations, and advanced data analytics solutions to B2B e-commerce clients. Additionally, Lifeist manages a butane hash oil extraction facility. Its operations extend to the distribution of both proprietary and licensed adult-use cannabis products, alongside supplying essential hardware like vaporizers and their accompanying accessories. The company further engages in biosciences and wider consumer wellness initiatives.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CAD0.04 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
17.7K
Beta
1.50
Float Shares
34.95M
Free Float %
92.2%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+12.50% +12.50% +12.50% +28.57% -30.77% +12.50% -50.00% -95.00% -98.98% -97.75% -92.50%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.04
DCF (Unlevered) 0.03 -27.5%
DCF (Levered) 0.01 -70.7%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-232.81
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -57.7% Q1'26: +20.6% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    -73.4% Q1'26: +82.8% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    -1,236.0% Q1'26: -591.3% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    -961.1% Q1'26: -273.9% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    -656.5% Q1'26: -146.6% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +19.2% Q1'26: +0.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.44) × ERP
WACC = 100% × Ke + 0% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 0.03 Current price: 0.04
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Nov 2020
actual 		Nov 2021
actual 		Nov 2024
actual 		Nov 2025
actual 		Nov 2026
1 Rev. Ana.
1 EPS Ana. 		Nov 2027
1 Rev. Ana.
1 EPS Ana.
Revenue
25.10M
est: 23.78M (+5.5%)
21.15M
est: 35.47M (-40.4%)
588.8K
est: 23.78M (-97.5%)
249.4K
est: 23.78M (-99.0%)
23.78M
23.78M – 23.78M
+0.0% YoY
35.47M
35.47M – 35.47M
+49.1% YoY
EBITDA
-24.01M
est: -18.93M (-26.8%)
-20.25M
est: -28.23M (+28.3%)
-3.99M
est: -19.14M (+79.1%)
-2.39M
est: -19.14M (+87.5%)
-19.14M
-19.14M – -19.14M
+0.0% YoY
-28.54M
-28.54M – -28.54M
-49.1% YoY
EBIT
-26.20M
est: -19.95M (-31.3%)
-21.97M
est: -29.75M (+26.1%)
-4.02M
est: -19.95M (+79.9%)
-2.40M
est: -19.95M (+88.0%)
-19.95M
-19.95M – -19.95M
+0.0% YoY
-29.75M
-29.75M – -29.75M
-49.1% YoY
Net Income
-26.25M
est: -50.85M (+48.4%)
-23.80M
est: -44.50M (+46.5%)
-1.45M
est: -60.62M (+97.6%)
-2.99M
est: -60.62M (+95.1%)
-60.62M
-60.62M – -60.62M
+0.0% YoY
-53.04M
-53.04M – -53.04M
+12.5% YoY
SGA
23.78M
est: 52.34M (-54.6%)
21.53M
est: 78.05M (-72.4%)
4.61M
est: 94.53M (-95.1%)
2.45M
est: 94.53M (-97.4%)
94.53M
94.53M – 94.53M
+0.0% YoY
140.98M
140.98M – 140.98M
+49.1% YoY
EPS
-1.62
est: -1.60 (-1.3%)
-1.22
est: -1.40 (+12.9%)
-0.05
est: -1.60 (+97.2%)
-0.08
est: -1.60 (+95.1%)
-1.60
-1.60 – -1.60
+0.0% YoY
-1.40
-1.40 – -1.40
+12.5% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-11 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-08 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-07 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-06 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-05 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-04 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-01 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-30 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-29 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-28 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-27 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-24 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-23 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-22 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-20 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-17 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-2.85M
OE per share TTM
-0.08
Owner's Yield
-167.24%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
14.6%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-333.00
Shares Outstanding
37.89M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
David Hughes Chief Marketing Officer — male
Lachlan McLeod Interim CEO, CFO, Corporate Secretary & Director — male
Paul Neider Advisory Consultant — male
Tim Henley Advisory Consultant — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic